Loading company…
Vetanic develops animal regenerative medicine using induced pluripotent stem cell technology.
Founded in 2021 and based in Tokyo, Vetanic develops veterinary regenerative medicine using iPS cell technology. Its work includes canine iPS cells and mesenchymal stem cells for products addressing health issues in companion animals, particularly dogs. On August 24, 2022, it raised JPY 500 million in Series B funding from Keio Innovation Initiative and QB Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in